Type 1 Diabetes PBMC Donors: Disease-State Portfolio and Clinical Annotation

Type 1 diabetes research sits at the intersection of autoimmunity and beta cell biology. Programs studying islet antigen-specific T cells, Treg therapy, immune tolerance induction, or CAR-Treg approaches for T1D require donor material that reflects the immune dysregulation of the disease, not the immune profile of a healthy control.

OrganaBio’s Type 1 diabetes donor program provides PBMC material from T1D patients with documented clinical annotation, autoantibody status, diabetes duration, and HLA characterization. This page covers what clinical data we provide, which cell populations are most relevant for T1D research, and how to specify donors for your program.

Why T1D-Specific Donor Material Matters

The immune pathology of T1D is mediated primarily by autoreactive CD8+ and CD4+ T cells that recognize islet antigens including insulin, GAD65, IA-2, and ZnT8. These autoreactive T cells are present at low frequencies in peripheral blood even in healthy individuals but are expanded, activated, and functionally distinct in T1D patients. Studying these populations — their frequency, phenotype, T cell receptor repertoire, and responsiveness to antigen — requires donors in whom the autoreactive response is established.

Additionally, T1D is one of the primary indications driving Treg-based cell therapy development. Programs developing autologous or allogeneic Treg products for immune tolerance induction in T1D need primary Treg material from T1D donors to characterize the dysfunction they are trying to correct, and to test candidate therapeutic Treg products in disease-relevant assays.

OrganaBio’s T1D Donor Portfolio

T1D donors in OrganaBio’s disease-state program are characterized with clinical data appropriate for translational research programs. The standard annotation package includes:

• Confirmed T1D diagnosis. Donors are enrolled with confirmed T1D diagnosis, typically with onset before age 30 and insulin dependence from diagnosis.
• Diabetes autoantibody panel. Anti-GAD65, anti-IA-2 (ICA512), anti-ZnT8, and anti-insulin antibody status is documented where available. Autoantibody positivity identifies donors with confirmed autoimmune-mediated beta cell destruction as opposed to other forms of insulin-requiring diabetes.
• Disease duration from diagnosis. T1D donors range from recent-onset (within 2 years) to long-standing disease (greater than 10 years). Recent-onset T1D donors may retain residual C-peptide (indicating remaining beta cell mass), while long-standing T1D donors are typically C-peptide-negative. Both populations are relevant depending on the research question.
• C-peptide status. Residual C-peptide production indicates remaining beta cell function. Programs studying immune mechanisms near the time of beta cell destruction or developing preservation therapies need recent-onset, C-peptide-positive donors. Programs studying established T1D immune phenotype can use either population.
• HLA typing. T1D has among the strongest HLA associations of any autoimmune disease. HLA-DR3/DQ2 (DRB1*03:01/DQA1*05:01/DQB1*02:01) and HLA-DR4/DQ8 (DRB1*04/DQA1*03/DQB1*03:02) are the primary susceptibility haplotypes, present in over 90% of T1D patients. HLA-DQ2/DQ8 heterozygous donors have the highest genetic risk. OrganaBio provides HLA typing for T1D donors.
• Current insulin regimen and diabetes management. Insulin pump vs. multiple daily injections, HbA1c, and current blood glucose management documented for context.
• Other autoimmune conditions. T1D frequently co-occurs with other autoimmune conditions, particularly autoimmune thyroid disease. Co-occurring autoimmune conditions are documented.
• Donor age, sex, race/ethnicity, and BMI.

Key Cell Populations for T1D Research

Islet Antigen-Specific T Cells

CD8+ T cells reactive to islet antigens (preproinsulin, GAD65, IA-2, IGRP) are detectable by tetramer staining or antigen stimulation in peripheral blood from T1D donors. These populations are present at low frequency but are expanded relative to healthy controls and carry distinct activation and exhaustion markers that reflect the ongoing autoimmune process. OrganaBio’s T1D PBMCs support tetramer-based islet antigen-specific T cell detection and functional assays using peptide pools from the major T1D autoantigens.

Regulatory T Cells

Treg deficiency and dysfunction is documented in T1D. CD4+CD25+FoxP3+ Tregs from T1D donors show reduced suppressive capacity compared to healthy donor Tregs in co-culture suppression assays. This functional deficit is both the disease-relevant phenotype that Treg therapy programs aim to correct and the assay readout used to characterize candidate Treg products. T1D donor Tregs are required for programs where demonstrating improved Treg function over the disease-state baseline is part of the proof-of-concept package.

CD4+ Effector T Cell Subsets

Th1 cells are the dominant pathogenic subset in T1D-associated islet inflammation, driven by IL-12 and IFN-gamma signaling. T1D donors show elevated Th1 frequencies in peripheral blood relative to healthy controls. Th17 involvement in T1D is more variable and continues to be studied. Programs characterizing the Th1/Th17 balance in T1D or testing interventions targeting these subsets benefit from disease-state donors where these populations are at relevant frequencies.

B Cells and Autoantibody-Producing Cells

While T1D is primarily T cell-mediated, B cells play a role as antigen-presenting cells that activate islet antigen-specific T cells. B cells from T1D donors show altered activation thresholds and antigen presentation function. Programs studying B cell involvement in T1D pathogenesis or developing B cell-targeting approaches can use T1D donor PBMCs for these studies.

Research Applications

• Islet antigen-specific T cell detection and characterization using tetramers, stimulation assays, or single-cell TCR sequencing
• Treg functional assays comparing T1D donor Treg suppressive capacity to healthy controls and to candidate therapeutic Treg products
• CAR-Treg research using T1D donor T cells as both the starting material and the functional readout for islet antigen-targeting Treg constructs
• Drug candidate screening on primary T1D donor cells: IL-2 pathway modulators, co-stimulation blockade, antigen-specific tolerance induction
• Biomarker discovery across T1D donor PBMC transcriptomics and proteomics, stratified by disease duration and C-peptide status
• Population immunology studies comparing immune phenotype across T1D, at-risk (autoantibody-positive, non-diabetic) individuals, and healthy controls

Donor Selection Guidance for T1D Programs

Recent-onset vs. established disease. Specify whether your program needs recent-onset T1D donors (within 2 years of diagnosis, likely C-peptide positive) or established disease (greater than 5 years, typically C-peptide negative). The immune phenotype and available cell populations differ between these groups. Preservation therapy programs and programs studying active beta cell destruction need recent-onset donors. Programs studying the stable T1D immune landscape can use longer-standing disease donors.

HLA specification. If your program studies antigen-specific T cells or HLA class II-restricted immune responses, specify HLA type. DR3/DR4 heterozygous donors are the highest-risk genotype and are the most common in T1D cohorts. Programs using T1D antigen tetramers should confirm that the tetramer’s HLA restriction matches the donor’s HLA type.

Autoantibody positivity. If your program specifically requires confirmed autoimmune T1D (rather than other insulin-requiring conditions), request anti-GAD65 or anti-IA-2 positive donors. This is particularly important for programs where the mechanism of interest is antigen-specific and the target autoantigen needs to be confirmed in the donor.

Post-Thaw Specifications

OrganaBio’s quality standard for released disease-state cryopreserved PBMCs is greater than 80% post-thaw viability. T1D donor material is processed under the same receipt-to-processing standards that govern OrganaBio’s healthy donor program, preserving the phenotypic integrity of low-frequency cell populations that are particularly relevant for T1D research.

Frequently Asked Questions

Are T1D donors available with recent-onset disease?

Yes, though recent-onset T1D donors (within 2 years of diagnosis) are a smaller subset of the total donor pool than donors with established disease. Contact OrganaBio’s team with your specific requirements to check current availability and lead time for recent-onset donors with your required annotation.

Can I get matched T1D and healthy donor PBMCs for side-by-side comparison?

Yes. OrganaBio maintains an HLA-typed healthy donor pool processed under the same conditions as the disease-state program, enabling age- and sex-matched or HLA-matched healthy versus T1D comparisons processed under identical conditions at the same Cell Processing Center.

Is T1D PBMC material appropriate for GMP manufacturing use?

No. OrganaBio’s disease-state donors are for research use only (RUO). For clinical programs requiring starting material from T1D patients, contact OrganaBio’s clinical team to discuss program-specific requirements under the appropriate regulatory framework.

Requesting T1D Donor Material

To discuss T1D donor availability, clinical annotation options, and delivery timelines, contact OrganaBio’s team. Specify disease duration, C-peptide status requirements, HLA needs, and the cell populations most relevant to your research application.